Payment overview · 2025
General Payments
$907.07
50 reported records · 18 companies
Healthcare provider profile · identity verified
Darren E Killen, MD
Allopathic & Osteopathic Physicians|Family Medicine · KANSAS CITY, MO · NPI 1114920295
Verified facts
What the public records show
CMS Open Payments records show Darren E Killen, MD received $907.07 in general payments during 2025 across 50 reported records.
ViiV Healthcare Company accounted for 17.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $162.18 | 17.9% | 11 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $129.07 | 14.2% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $100.55 | 11.1% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $66.36 | 7.3% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $63.41 | 7.0% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $55.59 | 6.1% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $46.51 | 5.1% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $44.12 | 4.9% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $40.58 | 4.5% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $32.11 | 3.5% | 1 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$24.65 | 2.7% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.21 | 2.7% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $23.80 | 2.6% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $21.77 | 2.4% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $19.50 | 2.1% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $17.95 | 2.0% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.68 | 1.9% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.03 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $907.07 | 50 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $140.43 | 10 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $75.42 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $75.42 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $61.43 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $61.43 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $53.65 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $49.29 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $49.29 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $48.49 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $46.51 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $46.51 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $44.12 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $39.12 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $33.71 | 2 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $32.11 | 1 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $24.65 | 1 | 2025 |
Source payment records
|
|||||
| STRENSIQ Normalized: strensiq |
Biological | Alexion Pharmaceuticals, Inc. | $24.21 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $23.80 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $21.88 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $21.77 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $19.50 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $17.95 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.68 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $17.07 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $17.03 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.95 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 71 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 45 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
71 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
45 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 249 | 73 |
| Atorvastatin Calcium | Atorvastatin Calcium | 175 | 50 |
| Alprazolam | Alprazolam | 153 | 32 |
| Valsartan | Valsartan | 151 | 42 |
| Levothyroxine Sodium | Levothyroxine Sodium | 118 | 30 |
| Lisinopril | Lisinopril | 107 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 104 | 27 |
| Omeprazole | Omeprazole | 98 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 94 | 24 |
| Amlodipine Besylate | Amlodipine Besylate | 92 | 27 |
| Metformin Hcl | Metformin Hcl | 91 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 87 | 28 |
| Trazodone Hcl | Trazodone Hcl | 81 | 27 |
| Losartan Potassium | Losartan Potassium | 74 | 22 |
| Mounjaro | Tirzepatide | 71 | 12 |
| Bupropion Xl | Bupropion Hcl | 68 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 67 | 20 |
| Gabapentin | Gabapentin | 66 | 19 |
| Allopurinol | Allopurinol | 65 | 16 |
| Meloxicam | Meloxicam | 60 | 21 |
| Montelukast Sodium | Montelukast Sodium | 59 | 19 |
| Sertraline Hcl | Sertraline Hcl | 59 | 18 |
| Alendronate Sodium | Alendronate Sodium | 57 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 57 | 15 |
| Tramadol Hcl | Tramadol Hcl | 55 | 16 |
| Temazepam | Temazepam | 53 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 51 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 48 | 14 |
| Simvastatin | Simvastatin | 46 | 14 |
| Naproxen | Naproxen | 45 | suppressed |
| Ozempic | Semaglutide | 45 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 42 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | suppressed |
| Clonazepam | Clonazepam | 37 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 33 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 33 | suppressed |
| Ezetimibe | Ezetimibe | 32 | 11 |
| Valacyclovir | Valacyclovir Hcl | 29 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | 11 |
| Prednisone | Prednisone | 28 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 21 |
| Jardiance | Empagliflozin | 25 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Potassium Chloride | Potassium Chloride | 25 | suppressed |
| Eszopiclone | Eszopiclone | 24 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Lorazepam | Lorazepam | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Famotidine | Famotidine | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Carvedilol | Carvedilol | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 18 | 11 |
| Glimepiride | Glimepiride | 17 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 16 | suppressed |
| Furosemide | Furosemide | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Testosterone | Testosterone | 15 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $907.07 · 50 records | ViiV Healthcare Company | AIRSUPRA, APRETUDE, EVENITY, FARXIGA, FREESTYLE LIBRE 3, IBSRELA, JARDIANCE, LEQVIO, Leqembi, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, STRENSIQ, Symbravo, Tymlos, UBRELVY, VALTOCO, VRAYLAR, WATCHMAN FLX, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error